会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Method of detecting bladder cancer
    • 检测膀胱癌的方法
    • US08999296B2
    • 2015-04-07
    • US12988621
    • 2009-04-21
    • Keiji InoueMasahiro IshizukaTohru Tanaka
    • Keiji InoueMasahiro IshizukaTohru Tanaka
    • A61K49/00A61K31/198A61K41/00
    • A61K49/0021A61K41/0061Y10S514/814
    • Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.
    • 本发明提供口服或静脉内给药型敏化检测剂,其能够以更高的灵敏度检测膀胱癌,而不会对患者造成疼痛。 通过口服或静脉内施用包含5-氨基乙酰丙酸(ALA),其衍生物或其盐的膀胱癌敏化检测剂,通过尿道插入摄像机系统,并将380-440nm的蓝光 照射以观察红色荧光部分。 此外,插入VLD-M1,照射405nm的蓝色光,以观察红色光部分的荧光强度(相对强度)。 对于口服给药,在施用前将20mg / kg(最多1g)的ALA溶于50mL的5%葡萄糖溶液中。
    • 6. 发明申请
    • METHOD OF DETECTING BLADDER CANCER
    • 检测乳腺癌的方法
    • US20110033386A1
    • 2011-02-10
    • US12988621
    • 2009-04-21
    • Keiji InoueMasahiro Ishizuka
    • Keiji InoueMasahiro Ishizuka
    • A61K49/00A61K31/197A61P35/00
    • A61K49/0021A61K41/0061Y10S514/814
    • Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.
    • 本发明提供口服或静脉内给药型敏化检测剂,其能够以更高的灵敏度检测膀胱癌,而不会对患者造成疼痛。 通过口服或静脉内施用包含5-氨基乙酰丙酸(ALA),其衍生物或其盐的膀胱癌敏化检测剂,通过尿道插入摄像机系统,并将380-440nm的蓝光 照射以观察红色荧光部分。 此外,插入VLD-M1,照射405nm的蓝色光,以观察红色光部分的荧光强度(相对强度)。 对于口服给药,在施用前将20mg / kg(最多1g)的ALA溶于50mL的5%葡萄糖溶液中。
    • 10. 发明授权
    • Coil apparatus and manufacturing method for the same
    • 线圈装置及其制造方法相同
    • US06633220B2
    • 2003-10-14
    • US09885084
    • 2001-06-20
    • Keiji InoueTsutomu Ishige
    • Keiji InoueTsutomu Ishige
    • H01F500
    • H01F27/2804H01F27/263
    • To prevent a substrate for mounting electronic components from being damaged when cores are rubbed together during assembly, a pair of core members sandwich a part of a coil pattern formed on the substrate from the top and bottom sides of the substrate, and the core members are held together by a core-combining member. A cover member is fixed to the substrate to cover the upper side of the core-combining member. Inclined ribs on the cover member raise the core-combining member by abutting against external inclined fates of leg portions of the core-combining member. A clearance thereby is formed between internal faces of a top bar portion of each core member and a surface of the substrate.
    • 为了防止在组装期间将芯体摩擦在一起时,用于安装电子部件的基板被损坏,一对芯体从基板的顶面和底面夹着形成在基板上的线圈图案的一部分,并且芯部件 由核心组合成员共同组成。 盖构件固定到基板以覆盖芯组合构件的上侧。 盖构件上的倾斜肋通过抵靠芯组合构件的腿部的外倾斜位置而升高芯组合构件。 因此,在每个芯构件的顶部杆部的内表面和基板的表面之间形成间隙。